<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04283539</url>
  </required_header>
  <id_info>
    <org_study_id>ircAE HS-3411</org_study_id>
    <nct_id>NCT04283539</nct_id>
  </id_info>
  <brief_title>Identification of Pathways to Mitigate Immune-Related Adverse Events With Cancer Immunotherapy</brief_title>
  <official_title>Identification of Pathways to Mitigate Immune-Related Adverse Events With Cancer Immunotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Jewish Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Jewish Health</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol is a prospective, observational study of participants receiving immunotherapy&#xD;
      (checkpoint inhibitors, CPI) for cancer therapy, testing the hypothesis that patients with&#xD;
      immune related cutaneous adverse events (ircAEs) have unique immunologic endotypes associated&#xD;
      with polarized immune responses.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Anticipated">February 2025</completion_date>
  <primary_completion_date type="Anticipated">February 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Immune Biomarkers</measure>
    <time_frame>30 days</time_frame>
    <description>cytokines and chemokines</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Presence of skin and circulating lipid biomarkers which occur during and after ircAEs</measure>
    <time_frame>30 days</time_frame>
    <description>Proportion of long-chain and short-chain ceramides Amounts and relative proportion of lysophosphatidylcholine molecular species. sphingosine-1-phosphate, platelet activating factor, leukotriene E4, prostaglandin F2α, endocannabinoids anandamide and 2- arachidonoylglycerol.&#xD;
Peripheral blood mononuclear cell RNA for expression of GRalpha, GRbeta, Vitamin D 24- Hydroxylase FK506 binding protein 5, mitogen induced kinase phosphatase 1, interleukin, tumor necrosis factor alphal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanisms associated with corticosteroid unresponsiveness in patients with ircAE</measure>
    <time_frame>12 months</time_frame>
    <description>Proportion of long-chain and short-chain ceramides Amounts and relative proportion of lysophosphatidylcholine molecular species. sphingosine-1-phosphate, platelet activating factor, leukotriene E4, prostaglandin F2α, endocannabinoids anandamide and 2- arachidonoylglycerol.&#xD;
Peripheral blood mononuclear cell RNA for expression of GRalpha, GRbeta, Vitamin D 24- Hydroxylase FK506 binding protein 5, mitogen induced kinase phosphatase 1, interleukin, tumor necrosis factor alphal</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">238</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>CPI with ircAE</arm_group_label>
    <description>Participants on check point inhibitors with immune related cutaneous adverse event</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no ircAE</arm_group_label>
    <description>Participants who do not have a cutaneous adverse event</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>systemic corticosteroid or biologic</intervention_name>
    <description>Treatment with systemic corticosteroids or biologic therapies (for corticosteroid refractory patients or these in which corticosteroids are not the treatment of choice)</description>
    <arm_group_label>CPI with ircAE</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult male or female with diagnosis of solid tumor&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of signed and dated informed consent form&#xD;
&#xD;
          2. Stated willingness to comply with all study procedures and availability for the&#xD;
             duration of the study&#xD;
&#xD;
          3. Male or female, &gt;18 yo&#xD;
&#xD;
          4. Diagnosis of solid tumor including, but not limited to, genitourinary/gynecologic,&#xD;
             lung, gastrointestinal and melanoma&#xD;
&#xD;
          5. Receiving, or prior to starting on, a checkpoint inhibitor&#xD;
&#xD;
          6. Grade ≥ 2 ircAE (CTCAE v 5.0) (for cohort 1 only)&#xD;
&#xD;
          7. An indication for system corticosteroids or biologic therapies as determined by the&#xD;
             treating physician (for cohort 1 only)&#xD;
&#xD;
          8. Life expectancy ≥ 12 weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Daily use of systemic steroid treatment in the past 4 weeks (prednisone &gt;10mg a day or&#xD;
             equivalent) except for indications other than the cutaneous adverse event, and/or as&#xD;
             an anti-emetic pre- or post-chemotherapy infusions.&#xD;
&#xD;
          2. Enrollment in any investigational drug trial with a drug that has not been approved&#xD;
&#xD;
          3. Taking other checkpoint inhibitors beyond anti-PD-(L)-1 or anti-CTLA-4 not yet&#xD;
             indicated/approved for use&#xD;
&#xD;
          4. Pregnancy&#xD;
&#xD;
          5. Known blood borne infectious disease&#xD;
&#xD;
          6. Current or pervious diagnosis of a leukemia or lymphoma&#xD;
&#xD;
          7. Unable to give consent for study participation&#xD;
&#xD;
          8. Life expectancy &lt; 12 weeks&#xD;
&#xD;
          9. Any other condition or diagnosis in the opinion of the investigator that would&#xD;
             interfere with the study results&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jessica Sussman</last_name>
    <phone>303-398-1717</phone>
    <email>sussmanj@njhealth.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Jewish Health and University of Colorado Denver</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cole Waliczek</last_name>
      <phone>303-270-2488</phone>
      <email>waliczekt@njhealth.org</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Kern, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario Lacouture, MD</last_name>
      <phone>646-608-2337</phone>
      <email>LacoutuM@mskcc.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 21, 2020</study_first_submitted>
  <study_first_submitted_qc>February 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2020</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Jewish Health</investigator_affiliation>
    <investigator_full_name>Jeffrey Kern</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>checkpoint inhibitor</keyword>
  <keyword>immuno-oncology</keyword>
  <keyword>cutaneous adverse events</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

